. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71 1. Foam Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71 2. Review of Data on Foam Formulations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72 3. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74 Abstract Consumers of topical formulations apply a wide spectrum of preparations, both cosmetic and dermatological, to their healthy or diseased skin. These formulations range in physicochemical nature from solid through semisolid to liquid. Pharmaceutical foams are pressurized dosage forms containing one or more active ingredients that, upon valve actuation, emit a fine dispersion of liquid and/or solid materials in a gaseous medium. Foam formulations are generally easier to apply, are less dense, and spread more easily than other topical dosage forms. Foams may be formulated in various ways to provide emollient or drying functions to the skin, depending on the formulation constituents. Therefore, this delivery technology should be a useful addition to the spectrum of formulations available for topical use; however, as yet, only a few are commercially available. Probably the most convincing argument for the use of foams is ease of use by the patient, and consumer acceptance. Most foam dosage forms used in dermatology to date have incorporated corticosteroids, although some products have also been used to deliver antiseptics, antifungal agents, anti-inflammatory agents, local anesthetic agents, skin emollients, and protectants. Although there is no clinical evidence that foam formulations are currently superior to other conventional delivery vehicles, these formulations have a clear application advantage and with continued developments in the science of supersaturation technology, it seems certain that foam delivery systems will retain their place in the dermatological and cosmetic armamentarium. TECHNOLOGY iN PRACTICE Am J Drug Deliv 2003; 1 (1): 71-75 1175-9038/03/0001-0071/$30.00/0Consumers of topical formulations apply a wide spectrum of preparations, both cosmetic and dermatological, to their healthy or diseased skin. These formulations range in physicochemical nature from solid through semisolid to liquid. Pharmaceutical foams are pressurized dosage forms containing one or more active ingredients that, upon valve actuation, emit a fine dispersion of liquid and/or solid materials in a gaseous medium. Foam formulations are generally easier to apply, are less dense, and spread more easily than other topical dosage forms. Foams may be formulated in various ways to provide emollient or drying functions to the skin, depending on the formulation constituents. Therefore, this delivery technology should be a useful addition to the spectrum of formulations available for topical use; however, as yet, only a few are commercially available. Probably the most convincing argument for the use of foams is ease of use by the patient, and consumer acceptance. Most foam dosage forms used in dermatology to date have incorporated corticosteroids, although some products have also been used to deliver antiseptics, antifungal agents, anti-inflammatory agents, local anesthetic agents, skin emollients, and protectants. Although there is no clinical evidence that foam formulations are currently superior to other conventional delivery vehicles, these formulations have a clear application advantage and with continued developments in the science of supersaturation technology, it seems certain that foam delivery systems will retain their place in the dermatological and cosmetic armamentarium. TECHNOLOGY iN PRACTICE Am J Drug Deliv 2003; 1 (1): 71-75 1175-9038/03/0001-0071/$30.00/0 © Adis International Limited. All rights reserved. Consumers of topical formulations apply a wide spectrum of preparations, both cosmetic and dermatological, to their healthy or diseased skin. These formulations range in physicochemical nature from solid through semisolid to liquid. Drug substances are seldom administered alone, but rather as part of a formulation, in combination with one or more nonmedical agents that serve varied and specialized pharmaceutical functions.[1] Drugs are administered topically for their action at the site of application, or for systemic effects. Drug absorption through the skin is enhanced if the drug substance is in solution, if it has a favorable lipid/water partition coefficient, and if it is a nonelectrolyte. For the most part, pharmaceutical preparations applied to the skin are intended to serve some local action and, as such, are formulated to provide prolonged local contact, with minimal systemic drug absorption. Drugs applied to the skin for their local action include antiseptics, antifungal agents, anti-inflammatory drugs, local anesthetics, skin emollients, and protectants.[1,2]
[1]
Eric W. Smith,et al.
Effect of Concentration and Degree of Saturation of Topical Fluocinonide Formulations on In Vitro Membrane Transport and In Vivo Availability on Human Skin
,
1999,
Pharmaceutical Research.
[2]
M. Lebwohl,et al.
A randomized, double‐blind, placebo‐controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis
,
2002,
International journal of dermatology.
[3]
S. Feldman,et al.
Betamethasone Valerate in Foam Vehicle Is Effective with
Both Daily and Twice a Day Dosing: A Single-Blind, Open-Label Study in the
Treatment of Scalp Psoriasis
,
2001,
Journal of cutaneous medicine and surgery.
[4]
C. Spencer,et al.
Clobetasol Propionate Foam, 0.05%
,
2001,
American journal of clinical dermatology.
[5]
S. Feldman,et al.
Topical corticosteroid in foam vehicle offers comparable coverage compared with traditional vehicles.
,
2000,
Journal of the American Academy of Dermatology.
[6]
Eric W. Smith,et al.
The Vehicle: The Pharmaceutical Carrier of Dermatological Agents
,
2000
.
[7]
V. Annese,et al.
Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
,
1999,
Italian journal of gastroenterology and hepatology.
[8]
G. Toti,et al.
[The topical therapy of ulcerative colitis. A multicenter study with beclomethasone dipropionate foam].
,
1999,
Minerva Chirurgica.
[9]
J. Hannigan,et al.
Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy
,
1999,
International journal of dermatology.
[10]
J. Marks,et al.
Prevention of sodium lauryl sulfate irritant contact dermatitis by Pro-Q aerosol foam skin protectant.
,
1999,
Journal of the American Academy of Dermatology.
[11]
H. Eichler,et al.
Transdermal penetration of diclofenac after multiple epicutaneous administration.
,
1998,
Journal of Rheumatology.
[12]
F. Witter,et al.
Quantitation of vaginally administered nonoxynol-9 in premenopausal women.
,
1997,
Contraception.
[13]
L. Daffonchio,et al.
Effects of a new foam formulation of ketoprofen lysine salt in experimental models of inflammation and hyperalgesia.
,
1995,
Arzneimittel-Forschung.
[14]
Alfonso R. Gennaro,et al.
Remington:the science and practice of pharmacy
,
1995
.
[15]
P. Cabitza,et al.
[Efficacy and tolerability of ketoprofen lysine salt foam for topical use in the treatment of traumatic pathologies of the locomotor apparatus].
,
1992,
La Clinica terapeutica.
[16]
N. G. Popovich,et al.
Pharmaceutical Dosage Forms and Drug Delivery Systems
,
1990
.
[17]
J. Duval,et al.
[A double-blind placebo-controlled study of a 2 percent foaming lotion of ketoconazole in a single application in the treatment of pityriasis versicolor].
,
1990,
Annales de dermatologie et de venereologie.
[18]
H. Beeuwkes,et al.
Microbiological tests on operating-theatre staff of a new disinfectant foam based on 1% chlorhexidine gluconate.
,
1986,
Journal of Hospital Infection.
[19]
W. Rauschmeier,et al.
[Clinical experiences with an antimycotic foam preparation with added prednisolone (Nystacorton foam)].
,
1986,
Pädiatrie & Pädologie.
[20]
B. W. Barry,et al.
Bioavailability and activity of topical corticosteroids from a novel drug delivery system, the aerosol quick-break foam.
,
1977,
Journal of pharmaceutical sciences.
[21]
Erwin K. Kastrup,et al.
Drug facts and comparisons
,
1977
.